Global Mortality of Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with Intravenous Immunoglobulin versus Steroid Therapies (P10-5.006)

Abstract

<h3>Objective:</h3> To investigate whether there is a significant difference in global mortality of CIDP patients who were either administered intravenous immunoglobulin (IVIg) versus steroids. <h3>Background:</h3> Treatment modalities for CIDP remain a frontier field and relative differences between treatments still require investigation. <h3>Design/Methods:</h3> We enacted a retrospective analysis using the New York Statewide Planning and Research Cooperative System (SPARCS) database to isolate patients with CIDP who also expired. Mortality was considered if the patient died or had a final state of hospice care. Age was limited to 18 years or older. Patients who received both IVIg and steroid treatment were excluded from analysis. <h3>Results:</h3> We identified 8,096 patients who were diagnosed with CIDP from 1998–2018. 496 patients in this period expired. 640 CIDP patients received steroid treatment and 47 of these patients died (7.3%). 1,868 CIDP patients received IVIG treatment and 87 of them died (3.6%). There is no significant difference between average age between patients receiving IVIG or steroids (70.79±12.86 vs 72.44±12.74; p=0.497) or gender (p=0.890) in the death cohort. Multivariate regression analysis performed on all patients has shown the likelihood of death is not significantly different between steroid use compared to patients not treated with steroids or IVIG (OR: 1.052; 95% CL: 0.743–1.488; p=0.777). However, the likelihood of death was significantly reduced in the group treated with IVIG compared to the patients who did not receive IVIG or steroids (OR: 0.593; 95% CL: 0.449–0.782; p&lt;0.001). <h3>Conclusions:</h3> Our preliminary data suggest a significant reduction in all cause of death in CIDP patients treated with IVIG. Work in progress to identify the contributions of other demographic and socioeconomic factors along with severity of associated comorbid conditions in CIDP mortality. <b>Disclosure:</b> Mr. Jaffry has nothing to disclose. Mr. Jaffry has nothing to disclose. Mr. Trivedi has nothing to disclose. Mr. Ors has nothing to disclose. Mr. Mostafa has nothing to disclose. Miss Shaikh has nothing to disclose. Mr. Mandava has nothing to disclose. Ms. Faiz has nothing to disclose. Dr. Khan has nothing to disclose. Dr. Souayah has received publishing royalties from a publication relating to health care.